Filing Flows › TG Therapeutics (TGTX) › Net income
TG Therapeutics (TGTX) net income by quarter
TG Therapeutics' net income was $7.8M in Q2 2026 (second quarter 2026), -61% from Q1 2026. Over the last 7 quarters it ranged from $5.1M (Q1 2025) to $391M (Q3 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $7.8M | -61% | -72% |
| Q1 2026 | $19.8M | -14% | +291% |
| Q4 2025 | $23.0M | -94% | -1% |
| Q3 2025 | $391M | 14× | — |
| Q2 2025 | $28.2M | +457% | — |
| Q1 2025 | $5.1M | -78% | — |
| Q4 2024 | $23.3M | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' net income?
TG Therapeutics' net income was $7.8M in Q2 2026 (second quarter 2026), -61% from Q1 2026.
How has TG Therapeutics' net income changed?
Over the last 7 quarters it ranged from $5.1M (Q1 2025) to $391M (Q3 2025).